| Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ... PLoS medicine 18 (5), e1003620, 2021 | 153 | 2021 |
| Post-operative stereotactic radiosurgery following excision of brain metastases: A systematic review and meta-analysis ZZ Akanda, W Hong, S Nahavandi, N Haghighi, C Phillips, DL Kok Radiotherapy and Oncology 142, 27-35, 2020 | 67 | 2020 |
| Financial toxicity in patients with cancer attending a public Australian tertiary hospital: A pilot study L McLean, W Hong, SA McLachlan Asia‐Pacific Journal of Clinical Oncology 17 (3), 245-252, 2021 | 16 | 2021 |
| Real-world outcomes of ribociclib and aromatase inhibitor use in first line hormone receptor positive, HER2-negative metastatic breast cancer V Wong, R de Boer, S Baron-Hay, R Blum, F Boyle, S Chua, K Clarke, ... Clinical Breast Cancer 22 (8), 792-800, 2022 | 12 | 2022 |
| Cancer clinical trial vs real‐world outcomes for standard of care first‐line treatment in the advanced disease setting L Kostos, W Hong, B Lee, B Tran, SW Lok, A Anton, G Gard, YH To, ... International Journal of Cancer 149 (2), 409-419, 2021 | 8 | 2021 |
| Description of the effect of patient flow, junior doctor supervision and pandemic preparation on the ability of emergency physicians to provide direct patient care A Lim, N Gupta, A Lim, W Hong, K Walker Australian Health Review 44 (5), 741-747, 2020 | 7 | 2020 |
| A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment … C Conduit, W Hong, F Martin, B Thomas, N Lawrentschuk, J Goad, ... Frontiers in Oncology 12, 931509, 2022 | 6 | 2022 |
| Biology and clinical implications of fecal occult blood test screen-detected colorectal cancer S Mendis, W Hong, S Ananda, I Faragher, I Jones, M Croxford, M Steel, ... JNCI Cancer Spectrum 6 (1), pkab100, 2022 | 6 | 2022 |
| CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906. C Conduit, PS Grimison, JH Lewin, AR Hansen, JF Lynam, AJ Weickhardt, ... Journal of Clinical Oncology 41 (16_suppl), TPS5100-TPS5100, 2023 | 5 | 2023 |
| Improving clinical trials using Bayesian adaptive designs: a breast cancer example W Hong, SA McLachlan, M Moore, RK Mahar BMC Medical Research Methodology 22 (1), 133, 2022 | 5 | 2022 |
| Personalizing first-line systemic therapy in metastatic colorectal cancer: is there a role for initial low-intensity therapy in 2021 and beyond? A perspective from members of … C Dunn, W Hong, P Gibbs, S Ackland, K Sjoquist, NC Tebbutt, T Price, ... Clinical colorectal cancer 20 (3), 245-255, 2021 | 5 | 2021 |
| Artificial intelligence measured 3D body composition to predict pathological response in rectal cancer patients MY Wei, K Cao, W Hong, J Yeung, M Lee, P Gibbs, IG Faragher, PN Baird, ... ANZ Journal of Surgery 94 (7-8), 1286-1291, 2024 | 4 | 2024 |
| An exploration of testicular cancer survivors’ experience of ejaculatory dysfunction following retroperitoneal lymph node dissection—a sub-study of the PREPARE clinical trial C Conduit, AD Hutchinson, M Leonard, S O.’Haire, M Moody, B Thomas, ... Journal of Cancer Survivorship, 1-10, 2023 | 4 | 2023 |
| Post-radiotherapy stage III/IV non-small cell lung cancer radiomics research: a systematic review and comparison of CLEAR and RQS frameworks K Tran, D Ginzburg, W Hong, U Attenberger, HS Ko European Radiology 34 (10), 6527-6543, 2024 | 3 | 2024 |
| A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma L Gately, C Mesía, JM Sepúlveda, S Del Barco, E Pineda, R Gironés, ... Journal of Neuro-Oncology 166 (3), 407-415, 2024 | 3* | 2024 |
| Long-term control of melanoma adrenal metastasis treated with radiotherapy B McCann, M Higgins, DL Kok, W Hong, R Alipour, MST Chua Melanoma Research 32 (3), 166-172, 2022 | 3 | 2022 |
| Real‐world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer M Loft, V Wong, S Kosmider, R Wong, J Shapiro, W Hong, R Jennens, ... Internal Medicine Journal 55 (1), 41-46, 2025 | 2 | 2025 |
| Circulating Tumor DNA (ctDNA) as a marker of residual disease and recurrence risk in resected stage I IV epithelial ovarian cancer (EOC). S Ananda | 2 | 2023 |
| Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer CY Chong, A Jalali, HL Wong, M Loft, R Wong, M Lee, L Gately, W Hong, ... Asia‐Pacific Journal of Clinical Oncology 18 (5), e363-e368, 2022 | 2 | 2022 |
| BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset? V Wong, M Lee, R Wong, J Tie, J Shapiro, J Desai, L Nott, S Steel, ... Targeted Oncology 16, 227-236, 2021 | 2 | 2021 |
Peter GibbsThe Walter and Eliza Hall Institute Of Medical ResearchEmail verificata su wehi.edu.au
